Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

952
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
952
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

983
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
983
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

330
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
330

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation - insights from acute and chronic electroanatomic remapping in the randomized SINGLE-SHOT CHAMPION trial.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Pulsed-Field Ablation with Two Different-Sized Pentaspline Catheters in Patients with Atrial Fibrillation.

Heart rhythm·2026
Same author

Predictors of pacing-induced cardiomyopathy in patients undergoing AV nodal ablation: insights from a Delphi process and retrospective cohort study.

European heart journal open·2026
Same author

Discrimination of atrial fibrillation burden using cardiac magnetic resonance imaging.

Heart rhythm O2·2026
Same author

PVI Durability After PFA or RFA in Persistent-AF: Insights From a Mandated Prospective Remapping Study.

JACC. Clinical electrophysiology·2026
Same author

Autonomic effects and ablation success after pulsed field and cryoballoon ablation: a SINGLE SHOT CHAMPION substudy.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026

Related Experiment Video

Updated: Feb 6, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

[Device therapy in heart failure].

Nikola Kozhuharov1, Christian Sticherling1, Beat Schär1

  • 11 Universitätsspital Basel, Kardiologie.

Therapeutische Umschau. Revue Therapeutique
|August 28, 2018
PubMed
Summary
This summary is machine-generated.

Device therapy, including cardiac resynchronisation therapy and implantable cardioverter defibrillators, offers improved survival and quality of life for select heart failure patients. These treatments are crucial despite medical therapy advances for this high-mortality condition.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Experiment Videos

Last Updated: Feb 6, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Area of Science:

  • Cardiology
  • Medical Devices
  • Clinical Medicine

Background:

  • Heart failure (HF) presents significant mortality and morbidity challenges.
  • Medical therapy for HF has advanced but has limitations.
  • A subset of HF patients remains vulnerable despite optimal medical management.

Purpose of the Study:

  • To highlight the role of device therapy in managing heart failure.
  • To discuss the benefits of cardiac resynchronisation therapy (CRT) and implantable cardioverter defibrillators (ICDs) in selected HF patients.

Main Methods:

  • Review of current treatment options for heart failure.
  • Focus on the application and patient selection for device-based therapies.
  • Analysis of the impact of CRT and ICDs on patient outcomes.

Main Results:

  • Device therapy, specifically CRT and ICDs, is a viable treatment option for carefully selected heart failure patients.
  • These interventions can lead to improvements in survival rates.
  • Enhanced quality of life is a key benefit observed in patients receiving device therapy.

Conclusions:

  • Cardiac resynchronisation therapy and implantable cardioverter defibrillators are important therapeutic options for specific heart failure populations.
  • Device therapy offers a chance to improve survival and quality of life in vulnerable HF patients.
  • Continued research and careful patient selection are essential for optimizing device therapy in heart failure management.